HIV/AIDS Therapy

Napo completes feasibility assessment of crofelemer for chronic diarrhea in HIV/AIDS

Published in Law and Health Weekly, January 20th, 2007

Napo Pharmaceuticals, Inc has completed a feasibility assessment at four U.S. investigative sites in preparation for a phase III pivotal trial of crofelemer for chronic diarrhea in people living with HIV/AIDS (CRO-HIV).

The objectives of the Institutional Review Board-approved study were to estimate potential enrolment rates using patient inclusion and exclusion criteria resembling those to be employed in the phase III CRO-HIV trial; to assess patient compliance by completing a daily diarrhea symptom diary; and to assess the ability of patients to abstain from medications prohibited by the protocol, including concomitant anti-diarrhea medications. Fifty-five...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2007-01-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry